

BXCL501 Journal Articles (available through Open Access at Journal Web sites)

- Citrome L, Preskorn SH, Lauriello J, Krystal JH, Kakar R, Finman J, De Vivo M, Yocca FD, Risinger R, Rajachandran L. Sublingual dexmedetomidine for the treatment of acute agitation in adults with schizophrenia or schizoaffective disorder: A randomized placebo-controlled trial. *Journal of Clinical Psychiatry* 2022; 83(6):22m14447.
 - [Link \(Journal\)](#)
- Citrome L, Risinger R, Rajachandran L, Robison H. Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed. *Advances in Therapy*. 2022 Oct;39(10):4821-4835.
 - [Link \(Journal\)](#)
- Preskorn SH, Zeller S, Citrome L, Finman J, Goldberg JF, Fava M, Kakar R, De Vivo M, Yocca FD, Risinger R. Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial. *Journal of the American Medical Association*. 2022 Feb 22;327(8):727-736
 - [Link \(Journal\)](#)

POSTERS

Request a copy of a poster: medinfo@bioxccltherapeutics.com

BXCL501 Human Phase I/PK Poster Presentations

- Risinger R, Preskorn, S, Kakar R, Ereshefsky L, Yocca FD. Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Determine the Efficacy, Safety, and Pharmacokinetics of BXCL501 (Sublingual Dexmedetomidine) in Agitation Associated with Schizophrenia or Related Disorders. Poster presented at the American College of Neuropsychopharmacology (ACNP), Dec 8 -11, 2019; Orlando, FL.
- Risinger R, Gorny S, Robison H, De Vivo M, Lathia C, Adedoyin A. Double-blind, Placebo-controlled Multiple Ascending Dose Study of BXCL501 with Concomitant Treatment with Antidepressant in Healthy Volunteers. Poster presented at the American Society of Clinical Psychopharmacology Annual Meeting, Miami, FL. May 28-31, 2024; Miami, FL.
- Adedoyin A, Preskorn S, Lathia C. Pharmacokinetics of Dexmedetomidine after a Single Sublingual Dose of BXCL501 in Patients with Agitation Associated with Schizophrenia. Poster presented at the International Society of Bipolar Disorders (ISBD), May 13-15, 2021

SERENITY Poster Presentations

- Citrome L, Preskorn S, Rajachandran L, Watson C, Risinger R. Dexmedetomidine Orally Dissolving Film (BXCL501) for the Treatment of Acute Agitation Associated with Schizophrenia or Bipolar Disorder: SERENITY I and SERENITY II Clinical Trials. Poster presented at Psych Congress, Oct 29-Nov 1, 2021; San Antonio, TX
- Preskorn S, Goldberg JF, Finman J, De Vivo M, Yocca F, Risinger R. BXCL501 Demonstrates Significant Reduction in Agitation across All Mood States (Depressed, Hypomanic, Manic) in Patients with Bipolar Disorder. Poster presented at the International Society of Bipolar Disorders (ISBD), May 13-15, 2021
- Citrome L, Preskorn SH, Zeller S, De Vivo M, Yocca FD, Risinger R. Effect of BXCL501 for Treating Acute Agitation in Patients with Bipolar Disorder. Poster presented at the International Society of Bipolar Disorders (ISBD), May 13-15, 2021
- Citrome L, Preskorn S, Rajachandran L, Risinger, R. Dexmedetomidine Orally Dissolving Film (BXCL501) for the treatment of Acute Agitation Associated with Schizophrenia or Bipolar Disorder: SERENITY I and SERENITY II Clinical Trials. Poster presented at the Neuroscience Education Institute (NEI), Nov 3-7, 2021; Colorado Springs, CO
- Preskorn S, Zeller S, Citrome L, Goldberg J, Risinger R. Novel Rapidly Effective Treatment of Agitation in Patients with Bipolar Disorders: BXCL501 – An Oral Dissolving Film. Poster presented at the American Psychiatric Association (APA), May 1-3, 2021;
- Citrome L, Lauriello J, Krystal JH, Risinger R. A Novel Rapidly Effective Treatment of Agitation for Schizophrenia with the Oral Dissolving Film BXCL501. Poster presented at the American Psychiatric Association (APA), May 1-3, 2021
- Zeller S, Citrome L, Goldberg J, Finman J, De Vivo M, Yocca F, Risinger R. Safety and Patient Acceptability of BXCL501 for Treating Acute Agitation in Patients with Bipolar Disorder. Poster presented at the International Society of Bipolar Disorders (ISBD), May 13-15, 2021
- Rajachandran L, Kwong M, Risinger R. Dexmedetomidine Orally Dissolving Film (BXCL501) for the Treatment of Acute Agitation Associated with Schizophrenia or Bipolar Disorder: SERENITY I and SERENITY II. Poster presented at the American Society for Hospital Pharmacists (ASHP), Dec 5-9, 2021
- Risinger R, Rajachandran L, Robison H. Agitation Associated with Schizophrenia or Bipolar Disorder: Sublingual Dexmedetomidine Film Efficacy by Baseline Agitation Level. Poster presented at the Psych Congress (PsychCon), September 6-10, 2023; Nashville, TN

- Citrome L, Risinger R, Rajachandran L, Robison L. Number Needed to Treat and Number Needed to Harm from Two Phase 3 Studies of Sublingual Dexmedetomidine for Treating Acute Agitation in Patients with Schizophrenia and Bipolar Disorder. Poster Presented at Psych Congress, Sep 17-20, 2022; New Orleans, LA.
- Citrome L, Preskorn S, Rajachandran L, Risinger R. Dexmedetomidine Sublingual Film for Acute Agitation Associated With Schizophrenia or Bipolar Disorder: Pooled Trial Data. Poster presented at the Society for Academic Emergency Medicine (SAEM) – May 10-13, 2022; New Orleans, LA
- Preskorn S, Citrome L, Rajachandran L, McCall-Perez F, Risinger R. Dexmedetomidine Sublingual Film: Post Hoc Analysis of PANSS-Excited Component Items in Acute Agitation Associated With Schizophrenia or Bipolar Disorder. Poster presented at the American Psychiatric Association (APA), May 21-25, 2022; New Orleans, LA.
- Weston P, Preskorn S, Citrome L, Risinger R, Rajachandran L. Sublingual Dexmedetomidine Demonstrates Significant Reduction in Agitation Across Baseline Severity in Patients With Bipolar Disorders. Poster presented at the International Society of Bipolar Disorders (ISBD), June 10-12, 2022
- Weston P, Robison H, Risinger R, Rajachandran L. Sublingual Dexmedetomidine for the Treatment of Acute Agitation Associated with Schizophrenia or Bipolar Disorder: Effect Size and Pooled Efficacy. Poster presented at the Academy of Consultation Liaison Psychiatry (ACLP), Nov 9-12, 2022; Atlanta, GA
- Robison H, Rajachandran R, Poisson B, Risinger R. Sublingual Dexmedetomidine for the Treatment of Acute Agitation Associated with Schizophrenia or Bipolar Disorder: Effect Size and Pooled Efficacy. Poster presented at the American Association of Psychiatric Pharmacists (AAPP), April 16-19, 2023; Orlando, FL

Preclinical Poster Presentations

- De Vivo M, Seth S, Dhull D, Postma F, Yocca FD. Dexmedetomidine Reduces Stress-Related Behaviors and Improves Sleep Parameters in Rodent Models. Poster presented at the Schizophrenia International Research Society (SIRS), Apr 17-21, 2021; Virtual.
- De Vivo M, Seth S, Sharma S, Dhull, D, Janssens H, Roeser J, Yocca FD. Dexmedetomidine – Highly Favorable Pharmacokinetic and Pharmacological Features for a CNS Therapeutic Drug. Poster presented at the American College of Neuropsychopharmacology (ACNP), Dec 8 -11, 2019; Orlando, FL.
- Postma F, Gupta R, Yocca F. Lack of Tolerance With Repeat Dosage of Dexmedetomidine in Rat for 21 Days as Measured by EEG. Poster Presented at American College of Neuropsychopharmacology (ACNP), Dec 4-7, 2022; Phoenix, AZ

TRANQUILITY Poster Presentations

- Risinger R, Rajachandran L, Robison H. A Phase Ib/II Multicenter, Randomized, Double Blind, Placebo Controlled, Ascending Dose Finding Study of BXCL501 in Agitation Associated with Dementia. Poster presented at the American Society of Clinical Psychopharmacology Annual Meeting, Miami, FL. May 28-31, 2024; Miami, FL.
- Risinger R, Rajachandran L, Robison H. A Phase Ib/II Study of BXCL501 in Agitation Associated with Dementia. Poster presented at the Alzheimer's Association International Conference, July 28-Aug 1, 2024; Philadelphia, PA.